ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

Score Distribution, Other Charts, On P01s

October 2, 1992

New Understanding of drug Resistance Exciting Revolution

September 17, 1982

PET Three Months After Therapy Provides Early Warning Of Need For Intervention

November 30, 2007

Hawaiian Have Highest Cancer Rate In U.S.

April 29, 1983

Organ Systems Program to Submit 10 More Concepts In Fall

July 10, 1987

As NCI Sets Deadline For B-06 Reanalysis, Fisher Lawyer Says Demand Is Illegal

February 3, 1995